Who Paid My Doc
A Phase 3, Open-Label, Randomized, Controlled, Multi Country Study to
Research payments
$6,835,852
Through program year 2024, $6,835,852 in research payments was reported against A Phase 3, Open-Label, Randomized, Controlled, Multi Country Study to, across 706 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2024 | Research | $41,687 | 13 |
| 2023 | Research | $5,365,253 | 572 |
| 2022 | Research | $1,428,911 | 121 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Michael McCartney Portsmouth, NH Named on 21 payments
- Rica Santiago North Charleston, SC Named on 17 payments
- David Browder Rocky Mount, NC Named on 17 payments
- Robert Ferrera Sacramento, CA Named on 16 payments
- Pedro Ylisastigui Fort Myers, FL Named on 16 payments
- Paul Wakefield Knoxville, TN Named on 14 payments
- Raman Purighalla Canonsburg, PA Named on 14 payments
- Robert Falcone Warren, NJ Named on 13 payments
- Kevin Cannon Winston Salem, NC Named on 13 payments
- Tamara Doehner Omaha, NE Named on 13 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.